Formosa Pharmaceuticals, founded in 2010 and based in Taipei, Taiwan, is a late-preclinical and clinical stage biotechnology company with assets in ophthalmology, oncology, and anti-infectives. APP13007, our lead program for the treatment of inflammation and pain after cataract surgery, is in Phase 3 studies in the United States, and is expected to gain approval in 2023. Our proprietary APNT nanoparticle formulation platform, from which APP13007 was developed, is available for licensing, CDMO services, or co-development. In the oncology space, we are developing TSY-0110, a biosimilar of Kadcyla®. TSY-0110 is an antibody-drug conjugate for the treatment of HER2+ metatstatic or early breast cancer.
Formosa Pharmaceuticals is backed by major shareholder, Formosa Laboratories (4746:TWSE), a GMP-certified producer and contract development and manufacturing provider of Active Pharmaceutical Ingredients. In October, 2021, Formosa Pharma was registered on the Emerging Stock Board of the Taipei Exchange (6838:TWO).
Partnerships and co-development by program:
o Formosa Laboratories: GMP CMC manufacturing, Injectable fill-finish
o EirGenix, Inc.: antibody manufacturing).
o AimMax Therapeutics: Co-development agreement
o China Grand Pharmaceutical Healthcare & Holdings: Greater China licensing
o Taipei Medical University: Co-development agreement
|2010||Formosa Pharmaceuticals founded|
|2011||Collaboration project MPT0E028 (API synthesis) with Taipei Medical University|
|2015||MPT0E028 initiates Phase I (Taiwan)|
|2017||Acquired Activus APNT formulation platform, ADC projects partner EirGenix|
|2019||APP13007 submitted US FDA IND (Phase II)|
|2020||APP13007 Phase II completion|
|2021||APP13007 initiates Phase III (US), Grand Pharmaceutical (China) enters license agreement with Formosa Pharmaceuticals for APP13007|
|2021||Listing on emerging stock board (6838:TWO)|